Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW (2008) Cancer Immunol Immunother 57: 1173-83 Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development. Petroziello MF, McCann JW, Gonsalves CF, Eschelman DJ, Anne PR, Sato T, Doyle LA, Frangos A, Brown DB (2011) AJR Am J Roentgenol 197: W169-74 Regional radioactive treatments for hepatocellular carcinoma. Gonsalves CF, Brown DB, Carr BI (2008) Expert Rev Gastroenterol Hepatol 2: 453-6 Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M (2007) J Vasc Interv Radiol 18: 553-61; quiz 562 Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes. Stuart JE, Tan B, Myerson RJ, Garcia-Ramirez J, Goddu SM, Pilgram TK, Brown DB (2008) J Vasc Interv Radiol 19: 1427-33 Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Bar Ad V, Eschelman DJ, Parker L, Doyle LA, Brown DB (2011) J Vasc Interv Radiol 22: 1373-9 Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? McCann JW, Larkin AM, Martino LJ, Eschelman DJ, Gonsalves CF, Brown DB (2012) J Vasc Interv Radiol 23: 661-7 Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. Piana PM, Bar V, Doyle L, Anne R, Sato T, Eschelman DJ, McCann JW, Gonsalves CF, Brown DB (2014) HPB (Oxford) 16: 336-41
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.